Cargando…
Stem cell transplantation for the treatment of end-stage liver disease
The past two decades have witnessed an explosion of research and clinical application of stem cells, transforming the field of regenerative medicine. Stem cell transplantation has already been performed to treat patients with cancer, liver diseases, and various types of chronic diseases. Indeed, ste...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323519/ https://www.ncbi.nlm.nih.gov/pubmed/30631395 http://dx.doi.org/10.4254/wjh.v10.i12.907 |
_version_ | 1783385782541615104 |
---|---|
author | Wu, Dong-Bo Chen, En-Qiang Tang, Hong |
author_facet | Wu, Dong-Bo Chen, En-Qiang Tang, Hong |
author_sort | Wu, Dong-Bo |
collection | PubMed |
description | The past two decades have witnessed an explosion of research and clinical application of stem cells, transforming the field of regenerative medicine. Stem cell transplantation has already been performed to treat patients with cancer, liver diseases, and various types of chronic diseases. Indeed, stem cell-based therapies are effective in many diseases, and provide novel insights into the treatment of end-stage liver disease. Several clinical trials have indicated the efficacy profiles of stem cell transplantation in patients with end-stage liver disease, including liver cirrhosis, liver failure, and liver tumors. Animal models of acute liver failure have also provided important insights into the safety, mechanisms, and efficacy of stem cell therapies. Nevertheless, excitement due to this promising field must be tempered with careful and calculated research. In particular, studies on the quality, safety, and efficacy of stem cell transplantation are needed to ensure that qualified products are tested in well-designed clinical trials and approved by governments. Therefore, further investigations are required to effectively balance the safety with the innovation of stem cell transplantation research toward the effective treatment of end-stage liver disease. |
format | Online Article Text |
id | pubmed-6323519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-63235192019-01-10 Stem cell transplantation for the treatment of end-stage liver disease Wu, Dong-Bo Chen, En-Qiang Tang, Hong World J Hepatol Editorial The past two decades have witnessed an explosion of research and clinical application of stem cells, transforming the field of regenerative medicine. Stem cell transplantation has already been performed to treat patients with cancer, liver diseases, and various types of chronic diseases. Indeed, stem cell-based therapies are effective in many diseases, and provide novel insights into the treatment of end-stage liver disease. Several clinical trials have indicated the efficacy profiles of stem cell transplantation in patients with end-stage liver disease, including liver cirrhosis, liver failure, and liver tumors. Animal models of acute liver failure have also provided important insights into the safety, mechanisms, and efficacy of stem cell therapies. Nevertheless, excitement due to this promising field must be tempered with careful and calculated research. In particular, studies on the quality, safety, and efficacy of stem cell transplantation are needed to ensure that qualified products are tested in well-designed clinical trials and approved by governments. Therefore, further investigations are required to effectively balance the safety with the innovation of stem cell transplantation research toward the effective treatment of end-stage liver disease. Baishideng Publishing Group Inc 2018-12-27 2018-12-27 /pmc/articles/PMC6323519/ /pubmed/30631395 http://dx.doi.org/10.4254/wjh.v10.i12.907 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Editorial Wu, Dong-Bo Chen, En-Qiang Tang, Hong Stem cell transplantation for the treatment of end-stage liver disease |
title | Stem cell transplantation for the treatment of end-stage liver disease |
title_full | Stem cell transplantation for the treatment of end-stage liver disease |
title_fullStr | Stem cell transplantation for the treatment of end-stage liver disease |
title_full_unstemmed | Stem cell transplantation for the treatment of end-stage liver disease |
title_short | Stem cell transplantation for the treatment of end-stage liver disease |
title_sort | stem cell transplantation for the treatment of end-stage liver disease |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323519/ https://www.ncbi.nlm.nih.gov/pubmed/30631395 http://dx.doi.org/10.4254/wjh.v10.i12.907 |
work_keys_str_mv | AT wudongbo stemcelltransplantationforthetreatmentofendstageliverdisease AT chenenqiang stemcelltransplantationforthetreatmentofendstageliverdisease AT tanghong stemcelltransplantationforthetreatmentofendstageliverdisease |